Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas Read more about Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer Read more about Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma Read more about DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma
PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS Read more about PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS
Upfront Surgical Resection for Osteosarcoma Read more about Upfront Surgical Resection for Osteosarcoma
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors Read more about A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 Read more about A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA-2
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC Read more about Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
(VELA) Study of BLU-222 in Advanced Solid Tumors Read more about (VELA) Study of BLU-222 in Advanced Solid Tumors